Journal of Clinical Psychopharmacology最新文献_第4页

All Patients With Catatonia Deserve Proper Diagnosis, Theragnosis, and Prognosis. 所有的紧张症患者都应该得到正确的诊断、诊断和预后。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-06-13 DOI: 10.1097/JCP.0000000000002038

João Gama Marques

引用次数: 0

What if STAR*D Had Been Placebo-Controlled? A Critical Reexamination of a Foundational Study in Depression Treatment. 如果STAR*D是安慰剂控制的呢？对抑郁症治疗基础研究的重新审视。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-06-13 DOI: 10.1097/JCP.0000000000002025

Kevin P Kennedy, Jonathan P Heldt, David W Oslin

{"title":"What if STAR*D Had Been Placebo-Controlled? A Critical Reexamination of a Foundational Study in Depression Treatment.","authors":"Kevin P Kennedy, Jonathan P Heldt, David W Oslin","doi":"10.1097/JCP.0000000000002025","DOIUrl":"https://doi.org/10.1097/JCP.0000000000002025","url":null,"abstract":"Background: The STAR*D trial's sequence of dose escalation, switching, and augmentation strategies has served as a model for most depression treatment guidelines. However, STAR*D was an open-label pragmatic trial that did not use a placebo control, which complicates the assessment of its outcomes. Most STAR*D treatment steps have now been studied in blinded placebo-controlled randomized trials, which could validate STAR*D and support the growing use of pragmatic trials in depression.Methods: This review evaluates outcomes from randomized controlled trials (RCTs) for the major STAR*D treatment steps: dose increase after inadequate response to an antidepressant (Level 1), switching the antidepressant after treatment nonresponse (Levels 2 and 3), augmenting an antidepressant with bupropion or buspirone (Level 2), augmenting an antidepressant with lithium or T3 thyroid hormone (Level 3), and using combination mirtazapine-venlafaxine (Level 4).Findings: RCTs have generally not replicated the findings of STAR*D. Of the major treatment steps, there is only positive evidence for lithium augmentation and α2-antagonist-serotonin-reuptake inhibitor combination. Limitations of this review include variation in the quality and quantity of comparable RCTs for each treatment level and differences in the inclusion criteria of RCTs and STAR*D.Conclusions: These findings raise questions about the evidence supporting widely used treatment strategies following an inadequate response to an initial antidepressant. They suggest that pragmatic trials should be interpreted cautiously in the absence of blinded placebo-controlled studies and point to the need for high-quality blinded clinical trials of second-step and third-step depression treatments.","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144284485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Aripiprazole-Associated Rhabdomyolysis: A Literature Review. 阿立哌唑相关横纹肌溶解：文献综述。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-06-13 DOI: 10.1097/JCP.0000000000002031

Jieru Ren, Jing Nie, Lihui Liu, Lei Sun, Ting Wang, Jiyong Wu

引用次数: 0

Evaluating the Discontinuation of Clozapine Due to Serious Side Effects: A Retrospective Cohort Study. 评价因严重副作用而停用氯氮平：一项回顾性队列研究。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-06-13 DOI: 10.1097/JCP.0000000000002035

Doğukan Koçyiğit, Rukiye Aktaş, Selim Coşkun, Elçin Özçelik Eroğlu, Emre Mutlu, Ayşe Elif Anil Yağcioğlu

{"title":"Evaluating the Discontinuation of Clozapine Due to Serious Side Effects: A Retrospective Cohort Study.","authors":"Doğukan Koçyiğit, Rukiye Aktaş, Selim Coşkun, Elçin Özçelik Eroğlu, Emre Mutlu, Ayşe Elif Anil Yağcioğlu","doi":"10.1097/JCP.0000000000002035","DOIUrl":"https://doi.org/10.1097/JCP.0000000000002035","url":null,"abstract":"Background: Clozapine remains underutilized due to its serious side effects, leading to negative prescriber attitudes. We aim to elaborate on serious side effects and discontinuation of clozapine in patients followed up in our center for 12 years.Methods: We retrospectively reviewed the medical records of patients admitted to the tertiary inpatient psychiatry service between 2010 and 2022. The cohort included patients with psychotic disorders (PD) or bipolar affective disorders (BAD), who discontinued clozapine during their hospitalization due to serious side effects. Rechallenge attempts and clinical outcomes after discontinuation were recorded.Results: Among 2298 patients, 568 (178 clozapine users, prescribing rate: 31.3%) were diagnosed with PD, and 420 (21 clozapine users, prescribing rate: 5%) were diagnosed with BAD. Fourteen patients with PD and 3 patients with BAD had a serious side effect of clozapine, which resulted in discontinuation in 15 patients (7.53%). The most frequent serious side effects were myocarditis or suspected myocarditis (5.02%) and agranulocytosis (1.50%). There was no sudden death, cardiac arrest, or need for intensive care. Of serious side effects, 88.2% occurred within 6 months after clozapine initiation. The most switched antipsychotic was olanzapine (57.1%) after discontinuation. Among those whose clozapine was discontinued, 20% of the patients were rechallenged, of which 66.6% were successful.Conclusions: Twelve years of observation shows that even life-threatening side effects of clozapine can be managed successfully. Our findings support that physicians should not miss patients' opportunities to benefit from clozapine due to their concern about serious side effects. Lastly, rechallenge is an option even if serious side effects occur in certain conditions.","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144284472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-Term Misuse of Megestrol Acetate Associated With Immunocompromise, Complicated by Esophageal Candidiasis, Hypogonadism, and Adrenal Insufficiency in Treatment-Resistant Depression. 难治性抑郁症患者长期滥用醋酸甲地孕酮伴免疫功能低下、并发食道念珠菌病、性腺功能减退和肾上腺功能不全

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-06-13 DOI: 10.1097/JCP.0000000000001983

Hsin Fang, Chih-Chung Huang, Chia-Yi Yao, Shin-Chang Kuo, Chun-Yen Chen, Chia-Ling Chen, Yi-Wei Yeh

引用次数: 0

Recurrent Ziconotide-Associated Delirium and Psychosis: A Case Report. 复发性齐iconotide相关谵妄和精神病1例报告。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-06-13 DOI: 10.1097/JCP.0000000000002021

Greg Noe, Arlen Gaba, Sahil Munjal

引用次数: 0

Detecting Anxious Distress, an Important Mood Specifier. 发现焦虑困扰，一个重要的情绪指示。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-06-06 DOI: 10.1097/JCP.0000000000002032

Mark J Berber

引用次数: 0

Response to the Letter to the Editor on "Clonidine and Trihexyphenidyl in Clozapine-Induced Hypersalivation". 关于“氯氮平引起的高涎症中的可乐定和三苯基”致编辑信的回应。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-06-06 DOI: 10.1097/JCP.0000000000002023

Puangpet Pansawat, Wattanapong Pansawat, Sipanat Silaket, Teeraporn Sadira Supapaan, Tuanthon Boonlue

引用次数: 0

Use of Intramuscular Midazolam, Diphenhydramine, and Haloperidol in Acute Agitation Management in a Psychiatric Emergency Department. 肌注咪达唑仑、苯海拉明和氟哌啶醇在精神科急诊科急性躁动管理中的应用

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-06-06 DOI: 10.1097/JCP.0000000000002027

Andrew M Williams, Rachel Mong, Kuniko Chijiwa, Alaa Alabadi-Bierman, Brandon Q Tran, Phillip Huynh, Teressa Benbarka, Timothy Allison-Aipa

{"title":"Use of Intramuscular Midazolam, Diphenhydramine, and Haloperidol in Acute Agitation Management in a Psychiatric Emergency Department.","authors":"Andrew M Williams, Rachel Mong, Kuniko Chijiwa, Alaa Alabadi-Bierman, Brandon Q Tran, Phillip Huynh, Teressa Benbarka, Timothy Allison-Aipa","doi":"10.1097/JCP.0000000000002027","DOIUrl":"https://doi.org/10.1097/JCP.0000000000002027","url":null,"abstract":"Abstract: Background: Intramuscular (IM) lorazepam is administered to acutely agitated patients. During a lorazepam shortage, midazolam was selected as the IM benzodiazepine of choice at this study location. This study aims to explore the efficacy and safety of IM haloperidol, diphenhydramine, and midazolam in treating acutely agitated patients.Methods: A single center, retrospective chart review was conducted in adult patients who received IM diphenhydramine and haloperidol in combination with either midazolam (midazolam+) or lorazepam (lorazepam+) in a psychiatric emergency department (ED) during 2 identified lorazepam shortage periods. Multivariate ordinary least squares and logistic regression analyses were used to evaluate post-IM patients' conditions in behavioral activity rating scale (BARS) scores and the safety and tolerability of IM administrations.Results: A total of 174 patients met inclusion criteria, with 87 patients in the midazolam+ group (treatment) and 87 patients in the lorazepam+ group (control). Lorazepam+ was associated with a 9.4% greater decrease in BARS score than midazolam+ ( P <0.01). Midazolam+ administrations achieved a goal BARS score of 4 more frequently than lorazepam+ ( P <0.05). 18.4% more patients received a BARS score of 2, oversedation with lorazepam+ ( P <0.05). Lorazepam+ patients took nearly 3 hours (176 min) longer than midazolam+ to return to \"normal\" baseline behavior ( P <0.001). No statistically significant differences were detected in the incidence of hypotensive episodes or oxygen desaturation between groups.Conclusions: This is the first study to examine coadministration of intramuscular midazolam with haloperidol and diphenhydramine. Midazolam+ was effective at managing agitation and may be an alternative to lorazepam+.","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Xanomeline/Trospium Combination: Not Non-dopaminergic but a Novel Antidopaminergic Treatment for Schizophrenia. Xanomeline/Trospium联合：不是非多巴胺能，而是一种新的抗多巴胺能治疗精神分裂症。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2025-06-06 DOI: 10.1097/JCP.0000000000002028

Gavin P Reynolds

引用次数: 0